Hematocrit Test Devices Market

Hematocrit Test Devices Market Size

The global hematocrit test devices market size was valued at USD 3.8 billion in 2024 and is expected to exhibit growth at a CAGR of 4.4% from 2025 to 2034 period. The increase in hematocrit testing has corresponded with an increase in blood-related disorders such as anemia, polycythemia, and sickle-cell diseases that have on the whole increased over the world.

For instance, according to the World Health Organization, for example, anemia is one of the most widespread diseases which has, as of today, affected about 1.62 billion people globally which means 24.8 percent of the world’s population. Additionally, according to the Centers for Disease Control and Prevention (CDC), sickle cell disease affects about 100,000 Americans, and 1 out of every 365 births of Black or African-American phenotype has the condition. So, these medical conditions make it compulsory to monitor the levels of hematocrit frequently, which exponentially increases the demand for effective and affordable testing equipment.

Hematocrit testing devices are used to quantify the volumetric proportion of erythrocytes in blood within the diagnostic apparatus for hematocrit determination. It is useful for detecting anemia, dehydration, or polycythemia. Often, the outcome of the testing is ready within short periods of time and the results are accurate; the devices usually have the form of analyzers, meters, or point-of-care testing devices for the supplied blood sample directly.

Hematocrit Test Devices Market Trends

• The market is expanding at a blinding pace due to the advancement in technology for a non-invasive approach, the rising need for incorporated wearable health technology, and increased adoption of home care testing, among other factors contributing to the growth of the industry.
  
• Furthermore, there is a noticeable pattern of pursuing the miniaturization of hematocrit testing devices, which tend to be more accommodating. These small devices are easy to transport and operate remotely in the field and even by non-specialist medical personnel.
  
• Furthermore, increasing numbers of hematocrit test devices are connecting to electronic health record systems. This enables the sharing of information between different users of the healthcare system. This development improves the quality of care, patient management, and decision-making. Therefore, the above-stated reasons should strengthen the market.
  

Hematocrit Test Devices Market Analysis

Learn more about the key segments shaping this market

Download Free PDF

Based on product, the market is classified into instruments, reagents and consumables. The instruments segment is further bifurcated into hematocrit test analyzer and hematocrit test meter. The instruments segment generated the highest revenue of USD 2.2 billion in 2024.

• The rising cases of blood-related ailments, such as anemia, blood cancer, and other hematological conditions, lead to increasing hematocrit testing demand. Hematocrit test analyzers and meters are of utmost importance to assess the level of blood cells in a person’s blood for medical and diagnostic purposes.
  
• Moreover, advancements in technology have resulted in accurate and faster hematocrit testing. The innovations in hematocrit analyzers and meters provide more reliable diagnoses, which in turn increases their clinical usage and dominance within this segment of the market.
  

Based on modality, the hematocrit test devices market is classified into laboratory-based testing and point-of-care (POC) testing. The laboratory-based testing segment accounted for USD 2.5 billion in market revenue in 2024 and is anticipated to grow at a CAGR of 4.2% between 2025 to 2034 period.

• The various tests done for diagnosing medical conditions like anemia, polycythemia, and dehydration make use of laboratory hematocrit testing. These tests require precise measurement of hematocrit levels to ensure accurate treatment is provided to the patients. Due to the high level of accuracy that laboratory devices provide, they are the chosen method of diagnosis by clinicians all over.
  
• Laboratory tests of hematocrit are regarded as the most reliable due to the increase in the complexity of health conditions. Highly accurate readings from these tests provide healthcare professionals with necessary data for cases that involve more intricate patient profiles. Because of the demand in this segment of the market, constant growth is anticipated.
  

Based on application, the hematocrit test devices market is classified into anemia, congenital heart diseases, polycythemia vera, and other applications. The anemia segment dominated the market in 2024 with a market share of 45.8%.

• The most common form of ailment is anemia, and especially iron-deficiency anemia, which is seen globally. Iron-deficiency anemia is known to affect women, children, and the aged. Because cases of this ailment are on the rise, the demand for accurate diagnosis of anemia through precise hematocrit testing has increased as well.
  
• Additionally, due to mounting knowledge of anemia and its implication on health, sickness is now being subjected to more regular screenings than before. The early detection of anemia-related complications by treatment aids in ameliorating the issue and is facilitated by hematocrit tests, which increases the demand for such devices in clinical and point-of-care. Therefore, this is expected to increase segmental growth within the market.
  

Learn more about the key segments shaping this market

Download Free PDF

Based on end use, the hematocrit test devices market is segmented into hospitals, diagnostic laboratories, ambulatory surgical centers, and other end users. The hospitals segment dominated the market in 2024 and is anticipated to reach USD 3 billion by the end of the forecast period.

• Precise and dependable devices for accurate measurement are vital, and this is why hospitals have these complications, for the proper management of anemia, dehydration, or even polycythemia. This is the cause behind the increased demand for modern hematocrit test devices within domestic areas.
  
• Furthermore, the regularly growing number of hospital patients suffering from cardiovascular, renal, or even chronic diabetes is exponentially increasing along with the common issues of anemia or defective blood. For effective and efficient management and control of such issues, the manipulation of such hematocrit monitoring devices is utterly necessary.
  

Looking for region specific data?

Download Free PDF

U.S. hematocrit test devices market accounted for USD 1.4 billion market revenue in 2024 and is anticipated to grow at a CAGR of 3.9% between 2025 to 2034 period.

• Blood disorders that include anemia, polycythemia, and sickle cell disease are very common in the U.S. population. This high incidence of blood disorders necessitates reliable and accurate hematocrit table devices for both clinical and home healthcare monitoring. Therefore, the prevalence of these conditions increases the demand for dependable hematocrit test devices.
  
• Additionally, the nation has one of the best healthcare systems in the world, which is well-developed because of the existence of advanced diagnostic tools. This increases the continuous adoption of life-saving hematocrit test devices in hospitals, clinics, and diagnostic labs, which is a key factor, as these devices are needed for proper diagnosis and patient care.
  

Germany hematocrit test devices market is projected to grow remarkably in the coming years.

• Germany employs advanced medical care techniques and has well developed diagnostics, hence there are many hospitals, clinics, and other non-hospital blood diagnostic centers with the implements for hematocrit tests which aid in the appropriate detection of anemic conditions and other diseases making the country relevant for this equipment market.
  
• The marketplaces in Germany are beginning to expand due to reimbursement structures and a financing approach for routine testing on patients. Such measures increase the availability of hematocrit diagnostic devices.
  

Japan holds a dominant position in the Asia Pacific hematocrit test devices market.

• The older people living in Japan, which encompass 65 years and above, comprise a large part of the Japanese population. It is without a doubt that older populations suffer from a multitude of chronic ailments, most notably anemia, cardiovascular diseases, and kidney diseases, bringing forth the crucial need to regularly monitor their hematocrit levels. This greatly propels the market demand.
  
• Additionally, the Japanese government provides ample support for screening and preventive medicine at a national level. Regular checkups, health screenings, and blood tests for anemia are common practices in Japan. Due to this emphasis on preemptive medicine, the market for hematocrit test devices in other clinical places and non-clinical points in Japan has greatly surged.
  

Hematocrit Test Devices Market Share

The market has a number of competitive players, among them are Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, and Pointe Scientific. These companies develop and produce a wide range of hematocrit testing products, including automated analyzer systems, portable meters, and handheld point-of-care devices. Competitive advantage hinges on technology innovation as exemplified by heightened accuracy, speed, and the ability to interface with healthcare IT. These players tend to use more aggressive tactics to gain additional revenue, such as strategic partnerships, mergers, acquisitions, and investing in research and development.

USPs of Hematocrit Test Devices Market

• Reliable measurement of red blood cell levels for effective diagnosis.
  
• Compact, portable devices designed for ease of use in various settings.
  
• Delivers quick results, enabling timely clinical decisions.
  
• Suitable for anemia, dehydration, and other hematological assessments.
  

Hematocrit Test Devices Market Companies

Prominent players operating in the hematocrit test devices industry include:

• MENARINI Group
• Abbott
• BIO-RAD
• Boule
• Danaher
• Diatron
• EKF
• Roche
• HORIBA Medical
• Mindray
• NIHON KOHDEN
• Nova Biomedical
• SENSA CORE
• SIEMENS Healthineers
• Sysmex
  

Hematocrit Test Devices Industry News: 

• In July 2024, EKF Diagnostics announced the launch of its new Biosen C-Line, an advanced version of its industry-leading rapid hematocrit analyzer. It was designed to enhance usability with a new color touch screen and advanced connectivity, enabling seamless integration with hospital and laboratory IT systems. This innovation ensures quick and secure availability of patient results to clinicians. With this launch, the company strengthened its position in the hematocrit testing market, offering improved workflow efficiency and attracting healthcare facilities seeking advanced, connected solutions for enhanced patient care.
  

The hematocrit test devices market research report includes in-depth coverage of the industry with estimates and forecasts in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Instruments
  • Hematocrit test analyzer
  • Hematocrit test meter
• Reagents and consumables

Market, By Modality

• Laboratory-based testing
• Point-of-care (POC) testing

Market, By Application

• Anemia
• Congenital heart diseases
• Polycythemia vera
• Other applications

Market, By End Use

• Hospitals
• Diagnostic laboratories
• Ambulatory surgical centers
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE